STOCK TITAN

Artelo Biosciences Inc - ARTL STOCK NEWS

Welcome to our dedicated news page for Artelo Biosciences (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Artelo Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Artelo Biosciences's position in the market.

Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced groundbreaking research in the Pharmaceuticals journal highlighting the protective properties of ART27.13 in preventing muscle degeneration caused by cancer. The research supports the potential of ART27.13 as a supportive care therapy for cancer patients, with ongoing evaluation in the Cancer Appetite Recovery Study Phase 2a clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Artelo Biosciences, a clinical-stage pharmaceutical company, will be presenting two programs at Neuroscience 2023. One program focuses on ART26.12, an inhibitor that modulates signaling pathways related to depressive and anxiety-related behaviors. The other program showcases ART12.11, a cocrystal of cannabidiol and tetramethylpyrazine that has shown improved efficacy in a model of anxiety and depression. Artelo plans to file an IND application in the first half of 2024 for ART26.12 to treat neuropathic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences clinical trial
-
Rhea-AI Summary
Artelo Biosciences announces virtual medical expert webinar on cancer-related anorexia and cachexia treatment landscape, featuring lead candidate ART27.13 in Phase 2a clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
Rhea-AI Summary
Artelo Biosciences to present at EFIC Congress on the effects of FABP5 Inhibitor in peripheral neuropathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
conferences
-
Rhea-AI Summary
Artelo Biosciences plans to file IND application for ART26.12 in neuropathic pain, based on positive FDA feedback
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.6%
Tags
none
-
Rhea-AI Summary
Artelo Biosciences to present at Cannabinoid-Derived Drug Development Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.03%
Tags
conferences
Rhea-AI Summary
Artelo Biosciences, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
Rhea-AI Summary
Artelo Biosciences, a clinical-stage pharmaceutical company (Nasdaq: ARTL), reported $14.0 million in cash and investments as of June 30, 2023, with a cash runway expected to support operations into the second half of 2024. The company achieved multiple objectives during the second quarter, including initiating a Phase 2a trial for cancer-related anorexia and weight loss, presenting preclinical data from animal studies, and anticipating approval to move a novel treatment into the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
Artelo Biosciences Inc

Nasdaq:ARTL

ARTL Rankings

ARTL Stock Data

4.68M
3.20M
0.83%
0.78%
0.45%
Tobacco Manufacturing
Manufacturing
Link
United States
Solana Beach

About ARTL

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.